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Aims There is no cure for pulmonary arterial hypertension, but current approved treatment options include prostanoids,
endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors. The effect on survival of these compounds
has not been appropriately assessed in individual trials because of small sample size and short duration. We per-
formed a meta-analysis of all randomized controlled trials with drugs published in this condition.
Methods
and results
Trials were searched in the Medline database from January 1990 to October 2008. The primary analysis included only
studies with a placebo comparator arm, the sensitivity analysis also included studies comparing two active treatment
arms. The main outcome measure was all-cause mortality. Twenty-one trials were included in the primary analysis
(3140 patients) and two additional studies (59 patients) were included in the sensitivity analysis. Average duration
of the trials was 14.3 weeks. All-cause mortality rate in the control group was 3.8%. Active treatments were associ-
ated with a reduction in mortality of 43% (RR 0.57; 95% CI 0.35–0.92; P ¼ 0.023); the sensitivity analysis conﬁrmed a
reduction in mortality of 38% (RR 0.62; 95% CI 0.39–1.00; P ¼ 0.048).
Conclusion The results of this meta-analysis suggest an improvement of survival in the patients treated with the targeted thera-
pies approved for pulmonary arterial hypertension.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Pulmonary hypertension † Meta-analysis † Randomized controlled trials † Endothelin receptor antagonists †
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Introduction
Pulmonary arterial hypertension is a devastating, progressive
disease with increasingly debilitating symptoms.
1 Increased
pulmonary vascular resistance owing to obstructive proliferative
changes in the lung microcirculation results in extensive heart
structural changes, limits patients exercise capacity, and eventually
leads to right heart failure and premature death.
1
The pathogenesis of pulmonary arterial hypertension is poorly
understood, but an imbalance between vasoconstrictor/prolifera-
tive agents (e.g. endothelin) and vasodilator/antiproliferative sub-
stances (e.g. prostacyclin and nitric oxide) have been identiﬁed in
the lung vasculature.
2,3
There is no cure for pulmonary arterial hypertension, but
current approved treatment options include prostanoids,
endothelin-receptor antagonists, and the phosphodiesterase
type-5 inhibitors.
4 These therapies improve symptoms, exercise
capacity, haemodynamics, and outcome but the clinical relevance
of these effects have been recently challenged.
5–7 The main criti-
cisms include the limited improvements observed on the exercise
capacity and the short duration and the small sample size of the
individual studies which have precluded any insight on the
prognostic relevance of the treatments.
A meta-analysis on 16 randomized controlled trials (RCTs) per-
formed in pulmonary arterial hypertension
8 concluded that the
treatments ‘produced limited beneﬁts in clinical endpoints and
failed to support a signiﬁcant survival advantage’. However, the
meta-analysis did not consider six RCTs
9–14 published before its
submission, included both acute
15,16 and long-term studies and
included one study on patients with lung ﬁbrosis.
16
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doi:10.1093/eurheartj/ehp022We present the data of a meta-analysis on 23 RCTs
9–14,17–33
with drugs performed exclusively in pulmonary arterial hyper-
tension patients (only in one study a minority of patients with
inoperable chronic thrombo-embolic pulmonary hypertension
was included
23) published as of October 2008. We excluded
acute studies assessing only haemodynamic variables.
Methods
RCTs in patients with pulmonary arterial hypertension (Group 1
according to the Venice clinical classiﬁcation
34 of pulmonary hyperten-
sion) published in English from January 1990 to October 2008 were
identiﬁed by the commonly adopted approach of computer-based
literature search on the MEDLINE database (Figure 1). As we were
interested in the analysis of the effects on mortality, acute studies
assessing only haemodynamic variables were excluded. Twenty-three
RCTs with drugs (Tables 1 and 2) with these characteristics were
identiﬁed. Each study was used as a unit for statistical analysis. The
data were analysed by intention-to-treat including all randomized
patients.
Main outcome measure for the present analysis was all-cause
mortality, which was reported in all RCTs. The following additional
secondary parameters which were reported explicitly and clearly in
the text and/or tables of only part of the RCTs were also assessed:
hospitalizations owing to pulmonary arterial hypertension, exercise
capacity as assessed by the 6-min walk distance (6MWD),
35 NYHA/
WHO functional class improvement,
36 right atrial pressure, mean
pulmonary arterial pressure, cardiac index, and pulmonary vascular
resistance.
The primary analysis was performed in 21 RCTs in which a clear
identiﬁcation of a placebo comparator arm was possible. Two
additional RCTs
27,30 assessed two different, concurrently initiated
treatment regimens in naı ¨ve patients and the decision on which arm
is considered the reference ‘placebo’ comparator arm may be arbi-
trary. RCTs with patients on background treatment with approved
drugs for pulmonary arterial hypertension in which the addition of a
new active compound (combination therapy) was tested as compared
with placebo were included.
12,14,32,33 Studies with compounds that
were eventually not approved owing to lack of efﬁcacy
9,22,25 and
doses of approved drugs, which were not endorsed because less effec-
tive or for increased side effects
13,24,28,31 were also included. In the
three RCTs with epoprostenol,
17–19 a randomized control group
was included but it was not blinded because for ethical reasons tun-
nelled central venous catheters and portable pumps for placebo infu-
sion were not utilized.
A secondary, sensitivity analysis on total mortality was performed
including all 23 studies. In this case the reference ‘placebo’ comparator
arm in the two studies assessing two different, concurrently initiated
treatment regimens in naı ¨ve patients was arbitrarily identiﬁed: in the
BREATHE-2 study
27 the group treated with epoprostenol alone (as
compared with the association of epoprostenol and bosentan) and
in the SERAPH study
30 the bosentan arm (as compared with the
sildenaﬁl arm) were considered as control arms, respectively. These
regimens could be considered as ‘standard of care’ when the studies
were conceived and performed.
Statistical methods
Treatment effects for total mortality were evaluated as relative risks
(RR) according to the inverse variance ﬁxed-effect method.
37
In order to identify biases owing to the exclusion of trials from the
analysis, the continuity correction method was also used by adding
0.5 in each cell with null events. To conﬁrm the robustness of the
data in case of statistically signiﬁcant results (P , 0.05) of the
primary analysis,
38 the Mantel–Haenszel and the Peto ﬁxed-effect
methods were also tested.
Treatment effects for explicitly reported hospitalizations and
NYHA/WHO improvement were evaluated as RR according to the
inverse variance ﬁxed-effect method.
Number needed to beneﬁt (NNT) and number of avoided events
per 1000 treated patients were calculated applying the RR to the
control group event rate.
For exercise capacity (as assessed by 6MWD), right atrial pressure,
pulmonary arterial pressure, cardiac index, and pulmonary vascular
resistance (as assessed by right heart catheterization), we computed
the effect size of tested drugs by using the weighted mean difference,
which was calculated after subtracting from baseline the end-study
values in treated and control groups. When studies did not directly
supply the standard error of the mean (SEM) for the calculation of
effect size, it was estimated from the published data.
39 When
either the values at the end of follow-up or the SEM were not
reported in the article, they were manually calculated from ﬁgures
(if available).
Multi-arm studies
13,24,28,29,31 were assessed combining all active
arms in one and comparing it with the control group. The arms
testing doses of drugs, which were eventually not approved because
less effective or for increased side effects
13,24,28,31 were included.
The Cochran Q test and I-squared were used to assess the magnitude
of effect size heterogeneity. When the heterogeneity test reached
the formal level for statistical signiﬁcance to assess heterogeneity
(P , 0.10), the null hypothesis of homogeneity of the treatment
effects across the studies was rejected and the analysis was repeated
by calculating a random-effect model.
40
Additional analyses were performed according to the pharmaco-
logical category of tested drugs and disease severity (estimated using
the median value of the 6MWD at baseline).
All analyses were performed using Stata 9.0 (Stata Statistical Soft-
ware: Release 9.0, 2005. StataCorp LP, College Station, TX, USA).
Figure 1 Flow chart of the search strategy and selection of the
trials.
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Characteristics of the studies
Tables 1 and 2 show the 23 RCTs characteristics recruiting 3199
patients with pulmonary arterial hypertension that have been
published over a 18-year period (January 1990–October 2008,
Figure 1). In the 21 studies included in the primary analysis, 3140
patients were enrolled. Only in one study
23 57 patients with
non-operable chronic thrombo-embolic pulmonary hypertension
(Group 4
34) were recruited. Eight RCTs assessed the effects of
prostanoids (intravenous epoprostenol, subcutaneous treprostinil,
inhaled iloprost, and oral beraprost), eight RCTs assessed the
effects of endothelin receptor antagonists (oral bosentan,
sitxsentan, and ambrisentan), four RCTs assessed the effects of
the phosphodiesterase type-5 inhibitor sildenaﬁl, and one study
the effects of the thromboxane synthase inhibitor terbogrel.
Two studies
27,30 compared two different, concurrently initiated
treatment regimens in naı ¨ve patients: in the BREATHE-2 study,
the groups were treated with epoprostenol alone or with a
combination of epoprostenol and bosentan, respectively, and in
the SERAPH study, the groups were treated with bosentan
or sildenaﬁl, respectively. In four studies background therapy
with bosentan,
12,14 sildenaﬁl,
32 or epoprostenol,
33 respectively,
was allowed.
The average length of the study periods was 14.3+5.9 weeks
(range 8–36 weeks).
In 17 studies, the exclusive or predominant aetiology was
idiopathic pulmonary arterial hypertension, two studies included
exclusively patients with the scleroderma spectrum of diseases
19
or patients with Eisenmenger’s syndrome.
11
The majority of the patients included in the RCTs were in
NYHA/WHO functional class III, only one study included
exclusively NYHA/WHO functional class II patients.
32
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Table1 Randomized controlled trial characteristics
First author/year Ofﬁcial
acronym
Number of
patients
Active drug Comparator Study period
(weeks)
Etiology (%)
Rubin et al.
17 – 23 Epoprostenol Randomized controls* 8 IPAH (100)
Barst et al.
18 – 81 Epoprostenol Randomized controls* 12 IPAH (100)
Badesch et al.
19 – 111 Epoprostenol Randomized controls* 12 APAH (100)
Channick et al.
20 – 32 Bosentan Placebo 12 IPAH (84), APAH (16)
Langleben et al.
9 – 71 Terbogrel Placebo 12 IPAH (100)
Simmoneau et al.
21 – 470 Treprostinil Placebo 12 IPAH (58), APAH (42)
Galie ` et al.
22 ALPHABET 130 Beraprost Placebo 12 IPAH (48), APAH (52)
Olschewski et al.
23 AIR 203 Iloprost Placebo 12 IPAH (50), APAH (22),
CTEPH (28)
Rubin et al.
24 BREATHE-1 213 Bosentan Placebo 16 IPAH (70), APAH (30)
Barst et al.
25 – 116 Beraprost Placebo 36 IPAH (74), APAH (26)
Sastry et al.
26 – 22 Sildenaﬁl Placebo 12 IPAH (100)
Humbert et al.
27 BREATHE-2 33 Epoprostenol þ Bosentan Epoprostenol þ placebo 16 IPAH (82), APAH (18)
Barst et al.
28 STRIDE-1 178 Sitaxsentan Placebo 12 IPAH (53), APAH (47)
Galie ` et al.
29 SUPER-1 278 Sildenaﬁl Placebo 12 IPAH (64), APAH (30),
Other (6)
Wilkins et al.
30 SERAPH 26 Bosentan Sildenaﬁl 16 IPAH (88), APAH (12)
Singh et al.
10 – 20 Sildenaﬁl Placebo 8 IPAH (50), PAH-ES (50)
Galie ` et al.
11 BREATHE-5 54 Bosentan Placebo 16 PAH-ES (100)
Barst et al.
13 STRIDE-2 185 Sitaxsentan Placebo 18 IPAH (59), APAH (30),
Other (11)
McLaughlin et al.
12 STEP 67 Inhaled iloprost
† Placebo
† 12 IPAH (55), APAH (45)
Hoeper et al.
14 COMBI 40 Inhaled iloprost
† Placebo
† 12 IPAH (100)
Galie ` et al.
31 ARIES 394 Ambrisentan Placebo 12 IPAH (64), APAH (32),
Other (4)
Galie ` et al.
32 EARLY 185 Bosentan
‡ Placebo
‡ 24 IPAH (61),APAH (35),
Other(4)
Simonneau et al.
33 PACES 267 Sildenaﬁl
§ Placebo
§ 16 IPAH (79), APAH (21)
APAH, associated pulmonary arterial hypertension; CTEPH, chronic thrombo-embolic pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; PAH-ES,
pulmonary arterial hypertension associated with Eisenmenger syndrome.
*The randomized control group was included but it was not blinded because for ethical reasons, a tunnellized central venous catheter and a portable pump for placebo infusion
was not utilized.
†All patients were on background treatment with Bosentan.
‡11% of patients were on background treatment with Sildenaﬁl.
§All patients were on background treatment with Epoprostenol.
N. Galie ` et al. 396The 6MWD alone or in combination was the primary endpoint
in 17 studies; additional primary endpoints included maximal
oxygen consumption, treadmill exercise test duration, pulmonary
vascular resistance, right ventricular muscle mass, and systemic
blood oxygen saturation.
All-cause mortality
Overall mortality (Table 3, Figure 2) in the 21 studies included in
the primary analysis was 2.48% (78 of the 3140 patients). Mortality
in the actively treated group was 1.54% (28 of the 1825patients)
and in the placebo group was 3.80% (50 of the 1315 patients).
These cumulative data do not consider the different randomization
fractions and the different durations of the RCTs and should be
intended as descriptive.
The cumulative RR estimate of death was a reduction of 43%
(RR 0.57; 95% CI 0.35, 0.92; P ¼ 0.023) with the inverse variance
method (Figure 2), no heterogeneity (I-squared ¼ 0.0%; P ¼ 0.830)
was detected among studies. The analysis with the continuity
correction (P , 0.022), the Mantel–Haenszel and the Peto
methods (both P , 0.001) conﬁrmed the statistical signiﬁcance.
Number of patients to be treated (NNT) to prevent one death
was 61.6 and 16.2 (95% CI 2.7–24.0) deaths were prevented
in each 1000 patients treated; these data were based on a RR ¼
0.573 applied to the control group event rate.
With respect to the effects of the different classes of drugs
(prostanoids, thromboxane synthase inhibitors, endothelin
receptor antagonists, and phosphodiesterase type-5 inhibitors),
no statistically signiﬁcant between-group heterogeneity
(I-squared ¼ 0.0%; P ¼ 0.771) emerged in subgroup analyses in
total mortality (Figure 3) or between the subgroups testing each
of the treatments (I-squared ¼ 0.0%; P ¼ 0.830).
Cumulative RR estimate of death in active treatment groups
when compared with control groups stratiﬁed by baseline exercise
capacity according to the median value of the 6MWD of
343 m (Figure 4) did not show between-group heterogeneity
(I-squared ¼ 0.0%; P ¼ 0.825).
In the sensitivity analysis including all 23 studies, overall
mortality (Table 3) was 2.56% (82 of the 3199 patients).
Mortality in the actively treated group was 1.72% (32 of the
1861 patients) and in the placebo group was 3.74% (50 of the
1338 patients).
The cumulative RR estimate of death was a reduction of 38%
(RR 0.62; 95% CI 0.39, 1.00; P ¼ 0.048) with the inverse variance
method, no heterogeneity was apparent among studies
(I-squared ¼ 0.0%; P ¼ 0.784). Analysis with the continuity
correction (P , 0.044), the Mantel–Haenszel and Peto methods
(P , 0.004 and P , 0.003, respectively) conﬁrmed the statistical
signiﬁcance.
Figure 2 Cumulative RR estimate of death in active treatment groups when compared with control groups (RR [95% CI]). P ¼ 0.023 for the
overall estimate of the primary analysis by inverse variance method. Studies with no events in both groups (Table 3) were excluded.
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pulmonary arterial hypertension
Overall hospitalization rate in the eight RCTs (35%) reporting this
information (Tables 2 and 3) was 4.98% (81 of the 1625). Hospital-
ization rate in the actively treated group was 3.2% (32 of the 1015)
and in the placebo group was 8.03% (49 of the 610). These cumu-
lative data do not consider the different randomization fraction and
the different durations of the RCTs and should be intended as
descriptive.
The cumulative RR estimate of hospitalizations (Figure 5) was a
reduction of 61% (RR 0.39; 95% CI 0.25, 0.61; P , 0.001) with
the inverse variance method, whereas no heterogeneity was
apparent among studies (I-squared ¼ 0.0%; P ¼ 0.599).
NNT to prevent one hospitalization was 19.9 and 50.3 (95% CI
32.5, 61.9) hospitalizations were prevented in each 1000 patients
treated; these data were based on a RR ¼ 0.393 applied to the
control group event rate.
Six-minute walk distance
Investigational treatments signiﬁcantly improved exercise capacity
as assessed by the 6MWD. The overall heterogeneity test provided
statistically signiﬁcant results (I-squared ¼ 76.6%; P , 0.001). The
weighted mean improvement of exercise capacity assessed by
the random-effect model in patients allocated to active treatments
in the 19 RCTs (83%) reporting this parameter (see Supple-
mentary material online, Figure S1) was 35.61 m (95% CI 27.13,
44.08; P , 0.001) ranging from 210 to þ108 m. This average
improvement appears to be an increase of about 10.8% when com-
pared with the mean baseline values. Heterogeneity was related to
both, drug classes (P , 0.001) and to baseline exercise capacity
(P ¼ 0.001).
NYHA/WHO functional class
In the 13 RCTs (53%) reporting NYHA/WHO functional class data
(see Supplementary material online, Figure S2), investigational treat-
ments signiﬁcantly improved this parameter by at least one func-
tional class (RR 2.35; 95% CI 1.59, 3.48; P , 0.001). Statistical
tests indicated the existence of heterogeneous study results
(I-squared ¼ 56.2%; P ¼ 0.007) and data were assessed by the
random-effect model. Heterogeneity was related to both, drug
classes (P ¼ 0.044) and to baseline exercise capacity (P ¼ 0.086).
Haemodynamic parameters
Investigational treatments signiﬁcantly improved haemodynamic
parameters as assessed by right heart catheterization. The
.......................
...............................................................................................................................................................................
Table 2 Randomized controlled trial characteristics
First author/year Ofﬁcial
acronym
NYHA/WHO
functional class (%)
Primary endpoint Invasive haemodynamic
evaluation
Explicitly reported
hospitalizations
Reported
survival
I II III IV
Rubin et al.
17 – – 9 65 26 6MWD Yes No Yes
Barst et al.
18 – – – 74 26 6MWD Yes No Yes
Badesch et al.
19 – – 5 78 17 6MWD Yes No Yes
Channick et al.
20 – – – 100 – 6MWD Yes No Yes
Langleben et al.
9 – – 49 51 – 6MWD Yes No Yes
Simmoneau et al.
21 – – 11 81 8 6MWD Yes No Yes
Galie ` et al.
22 ALPHABET – 49 51 – 6MWD Yes No Yes
Olschewski et al.
23 AIR – – 59 41 6MWD&FC Yes No Yes
Rubin et al.
24 BREATHE-1 – – 91 9 6MWD No Yes Yes
Barst et al.
25 – – 52 48 – VO2 max Yes No Yes
Sastry et al.
26 – – 82 18 – TT No No Yes
Humbert et al.
27 BREATHE-2 – – 75 25 PVR Yes No Yes
Barst et al.
28 STRIDE-1 – 33 66 1 VO2 max Yes No Yes
Galie ` et al.
29 SUPER-1 – 39 58 3 6MWD Yes Yes Yes
Wilkins et al.
30 SERAPH 1 – 100 – RV mass No No Yes
Singh et al.
10 – – 40 55 5 6MWD No No Yes
Galie ` et al.
11 BREATHE-5 – – 100 – SaO2 and PVR Yes No Yes
Barst et al.
13 STRIDE-2 – 37 59 4 6MWD No Yes Yes
McLaughlin et al.
12 STEP – 1 94 5 6MWD Yes Yes Yes
Hoeper et al.
14 COMBI – – 100 – 6MWD No Yes Yes
Galie ` et al.
31 ARIES 2 38 55 5 6MWD No Yes Yes
Galie ` et al.
32 EARLY – 100 – – PVR and 6MWD Yes Yes Yes
Simonneau et al.
33 PACES 1 25 68 6 6MWD Yes Yes Yes
6MWD, six-minute walk distance; NYHA, New York Heart Association; PVR, pulmonary vascular resistance; RV, right ventricle; SaO2, systemic arterial blood oxygen saturation;
TT, treadmill exercise test duration; VO2max, maximal oxygen consumption at cardiopulmonary exercise test; WHO, World Health Organization.
N. Galie ` et al. 398weighted mean reduction in right atrial pressure in patients
allocated to active treatments in the 11 RCTs (48%) reporting
this parameter (see Supplementary material online, Figure S3)w a s
21.84 mmHg (95% CI 21.89, 21.80, P , 0.001) ranging from
1.00 to 26.20 mmHg. The weighted mean reduction in mean
pulmonary arterial pressure in patients allocated to active treatments
when compared with treatment groups in the 13 RCTs (57%)
reporting this parameter (see Supplementary material online, Figure
S4)w a s22.86 mmHg (95% CI 22.93, 22.77; P , 0.001) ranging
from 21.00 to 29.30 mmHg. The weighted mean increase in
cardiac index in patients allocated to active treatments in the 12
RCTs (52%) reporting this parameter (see Supplementary material
online, Figure S5) was 0.18 L/min/m
2 (95% CI 0.17, 0.19,
P , 0.001) ranging from 0.00 to 1.10 L/min/m
2. The weighted
mean reduction in pulmonary vascular resistance in patients
allocated to active treatments in the 13 RCTs (57%) reporting this
parameter (see Supplementary material online, Figure S6)w a s2
4.09 resistance units (95% CI 24.18, 23.99; P , 0.001) ranging
from 21.40 to 27.50 resistance units. Statistical tests indicated
the existence of heterogeneous study results for each of the
haemodynamic parameters (I-squared ranged from 87.6% to 98.3%;
P, 0.001) and data were assessed by the random-effect model.
Discussion
The results of this meta-analysis on RCTs performed in pulmon-
ary arterial hypertension patients show that the mortality in the
control groups is high, being approximately 3.8% in the 14.3
weeks of the mean observation period (about 1.1% per
month). This conﬁrms the severity of the condition even in the
stable and selected patients population included in RCTs. A
reduction in the overall mortality of 43% was observed in the
patients randomized to the active treatments when compared
with those randomized to the placebo control arms (21 RCTs);
a reduction of 38% was also conﬁrmed after the addition of
the two remaining RCTs, which included a concurrently initiated
active control arm. These results were observed even if the
average duration of the RCTs was limited to 14.3 weeks and
even with the inclusion of RCTs on compounds which were
eventually not approved by the Regulatory Agencies because of
lack of consistent efﬁcacy such as the thromboxane synthase
inhibitor, terbogrel
9 and the oral available prostanoid,
beraprost.
22,25
Subgroups analysis according to the different classes of drugs or
with baseline exercise capacity as assessed by 6MWD did not
Figure 3 Cumulative RR estimate of death in active treatment groups when compared with control groups stratiﬁed according to treatment
class (inverse variance method). Heterogeneity between groups: P ¼ 0.771. Studies with no events in both groups (Table 3) were excluded. RR,
relative risk.
Meta-analysis of RCTs in PAH 399show statistically signiﬁcant heterogeneity in the effects on mor-
tality. These data suggest that the results have not been driven
by one class of drugs or by a group of patients with a speciﬁc
disease severity.
The reasons for these non-heterogeneous results among differ-
ent classes of drugs targeting diverse pathobiological pathways are
not clear and may include speciﬁc disease characteristics, such as a
ceiling effect which can limit and homogenize the extent of the
beneﬁcial effects that any medical treatment can achieve. In
addition, the statistical power of the meta-analysis might not be
sufﬁcient to show a difference among drug classes or disease
severity groups.
The survival beneﬁt as suggested by the NNT evaluation appears
to be signiﬁcant because 61.6 patients are needed to be treated
for an average period of 14.3 weeks for preventing one death.
The favourable results on survival observed in the current
meta-analysis when compared with a previous reported
meta-analysis
8 may be explained by different reasons including a
more appropriate selection of the trials (excluding acute studies
and studies with different pulmonary hypertension aetiologies)
and a larger sample size of both, number of studies (þ44%) and
number of patients (þ63%).
The rate of explicitly reported hospitalizations owing to pul-
monary arterial hypertension observed in the control groups of
eight studies of this meta-analysis appears high being approximately
8% in an average period of 14.3 weeks. The reduction by 61% in
the rate of hospitalizations observed in the groups of patients
randomized to the active treatments appears to support the
clinical efﬁcacy of the targeted treatments for pulmonary arterial
hypertension: one hospitalization can be prevented treating 19.9
patients for the average observation period of 14.3 weeks.
However, these data were reported only in 35% of the RCTs of
this meta-analysis and a reporting bias based on whether results
tended to be favourable cannot be excluded.
The meta-analysis has conﬁrmed the improvement in exercise
capacity as assessed by 6MWD observed in all but two of the
18 studies reporting this parameter. These results are not surpris-
ing as the 6MWD has represented the primary endpoint for the
majority of the RCTs and both patients’ sample size and statistical
power were calculated according to the predicted change of this
parameter. The weighted average improvement was about 10.8%
when compared with baseline 6MWD but markedly hetero-
geneous results were observed among different studies ranging
from 210 to þ108 m.
....................... ....................... ....................... .......................
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Table 3 Number of patients who died or were hospitalized in the randomized phase of the clinical trials (intent-to-treat)
First author/year Active drug Comparator Active drug Comparator
Death Death Hospitalization* Hospitalization*
Yes No Yes No Yes No Yes No
Rubin et al.
17 11 0 39 N A N A N A N A
Barst et al.
18 0 41 8 32 NA NA NA NA
Badesch et al.
19 4 52 5 50 NA NA NA NA
Channick et al.
20 0 21 0 11 NA NA NA NA
Langleben et al.
9 1 45 0 25 NA NA NA NA
Simmoneau et al.
21 9 224 10 227 NA NA NA NA
Galie ` et al.
22 1 64 1 64 NA NA NA NA
Olschewski et al.
23 1 100 4 98 NA NA NA NA
Rubin et al.
24 1 143 2 67 6 138 9 60
Barst et al.
25 1 59 2 54 NA NA NA NA
Sastry et al.
26 0 10 1 11 NA NA NA NA
Humbert et al.
27 3 19 0 11 NA NA NA NA
Barst et al.
28 1 117 0 60 NA NA NA NA
Galie ` et al.
29 3 205 1 69 6 201 7 63
Wilkins et al.
30 1 13 0 12 NA NA NA NA
Singh et al.
10 0 10 0 10 NA NA NA NA
Galie ` et al.
11 0 37 0 17 NA NA NA NA
Barst et al.
13 0 123 0 62 2 121 4 58
McLaughlin et al.
12 0 34 0 33 0 34 4 29
Hoeper et al.
14 0 19 0 21 0 19 0 21
Galie ` et al.
31 4 257 5 128 9 252 11 121
Galie ` et al.
32 1 92 1 91 1 92 3 89
Simonneau et al.
33 0 134 7 126 8 126 11 120
NA, not assessed.
*Explicitly reported hospitalizations for pulmonary arterial hypertension.
N. Galie ` et al. 400Figure 4 Cumulative RR estimate of death in active treatment groups when compared with control groups stratiﬁed by the median of base-
line exercise capacity of the studies (inverse variance method). Studies with no events in both groups (Table 3) were excluded. Heterogeneity
between groups: P ¼ 0.825. 6MWD, six-minute walk distance; RR, relative risk.
Figure 5 Cumulative RR estimate of hospitalizations in active treatment groups when compared with control groups. P , 0.001 for the
overall estimate by inverse variance method. Studies with no events in both groups (Table 3) were excluded. RR, relative risk.
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WHO/NYHA functional class and cardiopulmonary haemo-
dynamic data. The improvement of one functional class was
observed more often in patients randomized to active treatments
even if only about one-third of the subjects achieved this result.
Also in this case a reporting bias based on whether results
tended to be favourable cannot be excluded.
Statistically signiﬁcant improvements in the haemodynamic data,
including mean pulmonary arterial pressure, cardiac index, pulmon-
ary vascular resistance, and right atrial pressure were observed.
The weighted mean improvements of these parameters appear
to be small to moderate ranging from a reduction of about 25%
in pulmonary arterial pressure and an increase of 8% of the
cardiac index to a reduction of about 229% of the pulmonary
vascular resistance.
The limitations of this meta-analysis include theprolonged period
of time between the publication of the ﬁrst and the last RCT (about
18 years), the different duration of the trials (ranging from 8 to 36
weeks), the lack of blindness in some studies,
17–19,30 the pooling
of multiple active treatment arms (potential alteration of the trial
structure), the report of secondary outcome parameters only in
part of the RCTs (possible reporting bias), and potential hetero-
geneity in the conduct of the trials and in the deﬁnition of hospital-
ization for pulmonary arterial hypertension in different RCTs
(no individual patients data were reviewed). On the other hand,
this meta-analysis, which considered all randomized patients
(intention-to-treat), also included studies with compounds which
were eventually not approved because of lack of efﬁcacy
9,22,25 and
doses of approved drugs which were not endorsed because less
effective or for increased side effects.
13,24,28,31
A publication bias, favouring the publication of positive studies,
also cannot be excluded. The funnel-plot analysis (plots of effect
estimates against standard error of the estimate) did not show
asymmetry (see Supplementary material online, Figure S7) and a
possible publication bias should not have inﬂuenced substantially
the results of this meta-analysis.
In conclusion, the results of this meta-analysis suggest an
improvement of survival in the patients treated with the targeted
therapies approved for pulmonary arterial hypertension. A
reduction in the hospitalization rate and favourable results on
exercise capacity, functional capacity, and haemodynamics were
also observed in the groups of RCTs reporting these data.
Despite these results, the current treatment strategy remains
inadequate because the mortality rate continues to be high and
the functional and haemodynamic impairments are still extensive
in many patients. The non-equivocal progresses observed recently
in the medical treatments of this condition are not yet sufﬁcient.
Additional efforts are required to explore new strategies including
RCTs with initial combination therapy, with new classes of drugs,
and with new designs including morbidity and mortality endpoints
and prolonged observation periods.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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